

## PATENT GRANTED IN CHINA FOR hTERT

- **Chinese Patent No. ZL 201580008934.2 granted to BARD1 by the People's Republic of China's Patent and Trademark Office**
- **Provides patent protection for hTERT in China until 2035**

**Melbourne, Australia, 2 December 2020:** BARD1 Life Sciences Limited (ASX:BD1) (**BARD1 or Company**) announces that it has been granted Chinese patent number ZL 201580008934.2 titled 'Method of Detecting Cancer'.

Chinese patent ZL 201580008934.2 covers the use of the Company's hTERT antibody to resolve inconclusive cytology and detect malignant cells.

BARD1 CEO Dr Leearne Hinch said: "This core patent family provides intellectual property protection for our hTERT test in China. As noted in our Quarterly Business Update, we have been working closely with our distributor and regulatory consultant in China to finalise the regulatory process to gain approval for marketing of hTERT in China. The granting of this hTERT patent is well timed for our anticipated regulatory approval and planned launch of hTERT in China in 2021."

The hTERT test is an immunocytochemistry (ICC) assay that detects hTERT, a component of telomerase, which is upregulated in most human epithelial cancers. The test is used as an adjunct to urine cytology, assisting in the diagnosis of bladder cancer.

*Authorised by the Company Secretary, Tony Di Pietro.*

- ENDS -

### COMPANY CONTACTS

**Dr Leearne Hinch**  
CEO  
E [leearne@bard1.com](mailto:leearne@bard1.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-executive Chairman  
E [geoff.cumming@bard1.com](mailto:geoff.cumming@bard1.com)  
M +61 417 203 021

## ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising best-in-class diagnostic solutions for healthcare professionals and patients. The cancer diagnostics portfolio includes the commercialised hTERT test used as an adjunct to urine cytology testing and diagnostic tests in development for ovarian, breast, lung, prostate and pancreatic cancers. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).

## FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.